
Please try another search
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Name | Age | Since | Title |
---|---|---|---|
Robert H. Dworkin | - | - | Chair of Scientific Advisory Board |
Todd C. Davis | 64 | 2025 | Director |
Peter S. Greenleaf | 55 | 2025 | Director |
Richard Malamut | 65 | 2023 | Independent Director |
Ezra Friedberg | 55 | 2021 | Independent Director |
Richard B. Baxter | - | 2025 | Independent Director |
Matthew Pauls | 54 | 2025 | Independent Director |
Scott M. Plesha | 60 | 2025 | CEO, President & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review